Testing a new cell therapy for advanced B-cell lymphoma that hasn't responded to other treatments

Plain-English translation of NCT07473167 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new cancer treatment called for people with B-cell lymphomas that have not improved or have returned after multiple rounds of chemotherapy. is a type of cell therapy that works by taking your own immune cells, genetically modifying them in a lab to better recognize and attack cancer cells, and then infusing them back into your body. The study aims to see whether this medication is safe and how well it works for people in your situation.

Many people with aggressive B-cell lymphomas run out of effective treatment options after standard chemotherapy fails. This medication offers a different approach by harnessing your own immune system, and researchers want to learn whether this strategy can help patients who have limited options left.

Do you qualify?

You likely qualify if…

you are 19 years old or older with a good overall health status
you have been diagnosed with a large B-cell lymphoma and it has either returned or stopped responding to at least two prior rounds of chemotherapy
you have at least one measurable tumor that can be tracked on imaging
your heart, lungs, and other major organs are functioning well enough to handle the treatment
you are able to undergo a procedure called leukapheresis, which collects immune cells from your blood

You likely don't qualify if…

you have serious side effects from your previous cancer treatments that have not resolved
you have cancer in your brain or spinal fluid
you have active infections (including HIV, hepatitis B or C, or other serious infections)
you have had a different type of cell therapy or gene therapy before
you are pregnant, breastfeeding, or unwilling to use birth control for at least 6 months after treatment

What participation looks like

You will first receive two chemotherapy drugs (fludarabine and cyclophosphamide) to prepare your body for the new treatment. Then your immune cells will be collected through leukapheresis—a procedure similar to blood donation where blood is drawn, cells are separated out, and the rest is returned to you. Your cells will be sent to a lab to be modified, and once ready, the treatment will be infused back into your bloodstream. You will be closely monitored for safety, with regular visits and blood tests over an extended period.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Seoul National University Hospital, Seoul, Seoul